Association of Common PALB 2 Polymorphismswith Breast Cancer Risk : ACase-Control Study
Peizhan Chen,Jie Liang,Zhanwei Wang,Xiaoyi Zhou,Lu Chen,Mian Li,Dong Xie,Zhibin Hu,Hongbing Shen,Hui Wang
2008-01-01
Abstract:Purpose:The PALB2 gene has an essential role in BRCA2-mediated DNA double-strand break repair and intra ^ S phase DNA damage checkpoint control, and its mutations are moderately associated with breast cancer susceptibility.This study was designed to investigate the common variants of PALB2 and their association with breast cancer risk. Experimental Design: Four single nucleotide polymorphisms (SNP; rs249954, rs249935, rs120963, and rs16940342) which tagged all 19 of the reported SNPs (minor allele frequency >0.05) covering PALB2 were selected and genotyped in 1,049 patients with breast cancer and 1,073 cancer-free controls in a female Chinese population. Results: Based on the multiple hypothesis testing with the Benjamini-Hochberg method, tagging SNPs (tSNP) rs249954, rs120963, and rs16940342 were found to be associated with an increase of breast cancer risk (false discovery rate ^ adjusted P values of 0.004, 0.028, and 0.049, respectively) under the dominant model. tSNP rs249954 was associated with a 36% increase of breast cancer risk [adjusted odds ratio (OR), 1.36; 95% confidence intervals (CI), 1.13-1.64; P = 0.001; TT/TC versus CC genotypes]. The adjusted OR for rs120963 was 1.25 (95% CI, 1.04-1.49; P = 0.014; CC/CT versusTTgenotypes). For rs16940342, the adjusted OR was1.21 (95% CI,1.02-1.45; P = 0.037; GG/GAversus AA genotypes). Based on an additive model, tSNPs rs249954 and rs120963 were associated with an increase of breast cancer risk (P = 0.005 and 0.019; respectively), with the false discovery rate ^ adjusted P values being 0.020 and 0.038, respectively. Conclusions:Our data suggest that the variants of PALB2 confer low-penetrance breast cancer susceptibility in a Chinese population. Breast cancer is the most common cancer of women, with an estimated 178,000 new cases and 40,000 deaths in the United States in 2007 (1). Although the incidence of breast cancer in China is one-fifth of that in the United States, there has been a recent increase in the incidence of this disease (2, 3). The incidence of breast cancer is about twice as common in women with first-degree relatives affected by the disease compared with the general population, and the risk ratio increases with increasing numbers of affected first-degree relatives. This indicates that hereditary factors are involved in the development of breast cancer (4). In the 1990s, mutations of BRCA1, BRCA2 , and TP53, which confer a high risk (5to 10-fold) of breast cancer, were identified (5–7). However, these mutations account for less than 5% of all patients with breast cancer, and less than 25% of those with familial cancers (8). Moderatepenetrance mutations of CHEK2, BRIP1 , and ATM, which are rare but interact with BRCA1 and/or TP53, confer a 2-fold risk of breast cancer, have also been identified (9–11). Breast cancer susceptibility is thought to be associated with a ‘‘polygenic’’ model, in which a number of loci contribute to susceptibility, with each locus contributing only a small effect (12). Obviously, common variants of the abovementioned six genes are good candidates for breast cancer susceptibility. Their associations with breast cancer have been evaluated by a number of research groups, but studies have found conflicting results or no significant association (13–20). To date, several genomewide association studies have been accomplished in which several novel susceptibility loci have been identified (21–24). Fanconi anemia (FA) is an autosomal recessive disorder characterized by cellular hypersensitivity to DNA cross-linking Cancer Prevention and Susceptibility Authors’Affiliations: Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, ChineseAcademy of Sciences; Graduate School of the ChineseAcademy of Sciences and Laboratory of Reproductive Medicine, Cancer Center, Nanjing Medical University, Nanjing, China Received 2/19/08; revised 5/15/08; accepted 5/15/08. Grant support: Knowledge Innovation Program of the Chinese Academy of Sciences (KSCX-YW-R-73), Ministry of Science and Technology of China (2007CB947100), Science and Technology Commission of Shanghai Municipality (06DZ19021), PujiangTalent Program (06PJ14107), Food Safety Research Center and Key Laboratory of Nutrition and Metabolism of the Chinese Academy of Sciences, Department of Education (Innovative Key Grant 705023), and Program for Changjiang Scholars and Innovative ResearchTeam in University (IRT0631). The costs of publication of this article were defrayed in part by the payment of page charges.This article must therefore be hereby marked advertisement in accordance with18 U.S.C. Section1734 solely to indicate this fact. Note: P. Chen andJ. Liang contributed equally to this work. Requests for reprints: Hui Wang, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, P.R. China. Phone: 86-21-5492-0941; E-mail: huiwang@sibs.ac.cn or Hongbing Shen, Laboratory of Reproductive Medicine, Cancer Center, Nanjing Medical University, Nanjing 210029, P.R. China. Phone: 86-25-86862756; E-mail: hbshen@njmu.edu.cn. F2008 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-08-0429 www.aacrjournals.org Clin Cancer Res 2008;14(18) September15, 2008 5931 Research. on June 9, 2017. © 2008 American Association for Cancer clincancerres.aacrjournals.org Downloaded from agents and predisposition to cancer (25). Biallelic BRCA2 mutations cause the D1 subtype of FA, and the phenotype of this subtype is different from other types, with a high risk of childhood solid tumors (26). Two research groups recently identified a new subtype of FA, FA-N, which has a similar phenotype as FA-D1 but lacks BRCA2 mutations (26, 27). PALB2 (partner and localizer of BRCA2), a nuclear partner of BRCA2, is required for the intranuclear localization and stability of BRCA2 to execute its functions in error-free DNA double-strand break repair by homologous recombination and checkpoint control in intra–S phase DNA damage processes (28). Reduction of the expression of PALB2 by small interfering RNA, similar to a BRCA2 small interfering RNA, sensitized HeLa cells to mitomycin C, and resulted in a phenotype typical of FA (28). Because the defects in PALB2 were related to this new FA subtype, and affected subjects had a tendency to develop childhood cancer, PALB2 is also known as FANCN (FA complementation group N). In a subsequent study in the United Kingdom, monoallelic truncating mutations of PALB2 were found to be associated with a 2.3-fold increased risk of breast cancer in individuals with familial breast cancer (29). In Finland, a new PALB2 mutation, found in patients with or without a family history of breast cancer, conferred a 4-fold increased risk (30). Other studies have also found that truncating mutations in PALB2 conferred a moderate risk (31, 32). These data indicate that PALB2 mutations are moderatepenetrance susceptibility factors for breast cancer. Still, these mutations are rare, they occur in less than 1% of unselected breast cancers, and in less than 3% of patients with familial breast cancers (29–32). Considering the fact that PALB2 is important for FA and DNA double-strand break repair, common variants of PALB2 are candidates for genetic susceptibility to breast cancer. However, no previous study has investigated common single nucleotide polymorphisms (SNP) of PALB2 for association with breast cancer susceptibility. In the present study, we analyzed common SNPs of PALB2 and their associations with breast cancer risk in a case-control study using a SNPtagging method. Translational Relevance Although many genetic and environmental factors have been suggested to be involved in the etiology of breast cancer, the underlying molecular and genetic mechanisms are not fully understood. The present investigation is a continuation of our efforts to determine the genetic risk factors involved in the development of human breast cancer. In this study, we identified several common PALB2 polymorphisms that confer low-penetrance susceptibility to breast cancer. Our findings support the concept that genetic variants of the PALB2 gene confer breast cancer susceptibility and that this gene can be a potential target for the prevention and treatment of breast cancer. This discovery also offers an opportunity to use PALB2 as a biomarker in disease prediction and diagnosis of breast cancer. In addition, PALB2 variants, as personal genetic/ genomic profiling factors, can be used to predict cancer predisposition, leading to personalized approaches to cancer prevention and/or clinical management.Thus, these results may be applied to future clinical and basic cancer research and practice for improvements in the diagnosis, prevention, and treatment of breast cancer. Fig. 1. LD of the19 common variants (MAF > 0.05) based on the HapMap CHB database.The number in each square represents the correlation (r) between each pair of SNPs; the squares with no number represent r = 1. Four SNPs (rs120963, rs249935, rs249954, and rs16940342) were chosen to tag the19 common variants. Cancer Prevention and Susceptibility www.aacrjournals.org Clin Cancer Res 2008;14(18) September15, 2008 5932 Research. on June 9, 2017. © 2008 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Materials andMethods Study participants. In this study, 1,058 patients with clinically confirmed breast cancer were recruited from the Departments of Breast Surgery of the Cancer Hospital of Jiangsu Province (Nanjing), the First Affiliated Hospital of Nanjing Medical University, and the Nanjing Gulou Hospital, Jiangsu Province, China, between January 2004 and May 2007. A vast majority of participating subjects were included in a previously published study (33). All subjects were genetically unrelated ethnic Han Chinese women from hospitals in Nanjing City and surrounding regions served by t